Research programme: neuropsychiatric disorder therapeutics

Drug Profile

Research programme: neuropsychiatric disorder therapeutics

Alternative Names: IC 200131; ITI-333

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intra-Cellular Therapies
  • Class Small molecules
  • Mechanism of Action Dopamine D1 receptor modulators; Dopamine receptor modulators; NR2B N-Methyl D-Aspartate receptor modulators; Opioid mu receptor modulators; Serotonin 2A receptor antagonists; Serotonin receptor modulators; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Depressive disorders; Drug abuse; Mood disorders; Neurological disorders; Pain; Psychiatric disorders

Most Recent Events

  • 18 May 2017 Preclinical trials in Drug abuse and Depressive disorders in USA, before May 2017
  • 18 May 2017 Preclinical trials in Pain in USA, before May 2017 (Intra-Cellular Therapies website, June 2017)
  • 26 May 2014 New profile created from 9162647
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top